Plasma-to-tumour tissue integrated proteomics using nano-omics for biomarker discovery in glioblastoma
Abstract Glioblastoma (GB) is the most lethal brain cancer, with patient survival rates remaining largely unchanged over the past two decades. Here, we introduce the Nano-omics integrative workflow that links systemic (plasma) and localised (tumour tissue) protein changes associated with GB progress...
Saved in:
| Main Authors: | , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Nature Portfolio
2025-04-01
|
| Series: | Nature Communications |
| Online Access: | https://doi.org/10.1038/s41467-025-58252-0 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1850111797288239104 |
|---|---|
| author | Xinming Liu Hanan Abmanhal-Masarweh Olivia Iwanowytsch Emmanuel Okwelogu Kiana Arashvand Konstantina Karabatsou Pietro Ivo D’Urso Federico Roncaroli Kostas Kostarelos Thomas Kisby Marilena Hadjidemetriou |
| author_facet | Xinming Liu Hanan Abmanhal-Masarweh Olivia Iwanowytsch Emmanuel Okwelogu Kiana Arashvand Konstantina Karabatsou Pietro Ivo D’Urso Federico Roncaroli Kostas Kostarelos Thomas Kisby Marilena Hadjidemetriou |
| author_sort | Xinming Liu |
| collection | DOAJ |
| description | Abstract Glioblastoma (GB) is the most lethal brain cancer, with patient survival rates remaining largely unchanged over the past two decades. Here, we introduce the Nano-omics integrative workflow that links systemic (plasma) and localised (tumour tissue) protein changes associated with GB progression. Mass spectrometry analysis of the nanoparticle biomolecule corona in GL261-bearing mice at different stages of GB revealed plasma protein alterations, even at low tumour burden, with over 30% overlap between GB-specific plasma and tumour tissue proteomes. Analysis of matched plasma and surgically resected tumour samples from high-grade glioma patients demonstrates the clinical applicability of the Nano-omics pipeline. Cross-species correlation identified 48 potential GB biomarker candidates involved in actin cytoskeleton organisation, focal adhesion, platelet activation, leukocyte migration, amino acid biosynthesis, carbon metabolism, and phagosome pathways. The Nano-omics approach holds promise for the discovery of early detection and disease monitoring biomarkers of central nervous system conditions, paving the way for subsequent clinical validation. |
| format | Article |
| id | doaj-art-97059ea25cde4b0ba7d54f9342479431 |
| institution | OA Journals |
| issn | 2041-1723 |
| language | English |
| publishDate | 2025-04-01 |
| publisher | Nature Portfolio |
| record_format | Article |
| series | Nature Communications |
| spelling | doaj-art-97059ea25cde4b0ba7d54f93424794312025-08-20T02:37:33ZengNature PortfolioNature Communications2041-17232025-04-0116111410.1038/s41467-025-58252-0Plasma-to-tumour tissue integrated proteomics using nano-omics for biomarker discovery in glioblastomaXinming Liu0Hanan Abmanhal-Masarweh1Olivia Iwanowytsch2Emmanuel Okwelogu3Kiana Arashvand4Konstantina Karabatsou5Pietro Ivo D’Urso6Federico Roncaroli7Kostas Kostarelos8Thomas Kisby9Marilena Hadjidemetriou10NanoOmics Lab, Division of Cancer Sciences, School of Medical Sciences, Faculty of Biology, Medicine and Health, The University of ManchesterNanoOmics Lab, Division of Cancer Sciences, School of Medical Sciences, Faculty of Biology, Medicine and Health, The University of ManchesterNanoOmics Lab, Division of Cancer Sciences, School of Medical Sciences, Faculty of Biology, Medicine and Health, The University of ManchesterNanoOmics Lab, Division of Cancer Sciences, School of Medical Sciences, Faculty of Biology, Medicine and Health, The University of ManchesterNanoTherapeutics Lab, Division of Cell Matrix Biology and Regenerative Medicine, School of Biological Sciences, Faculty of Biology, Medicine and Health, University of ManchesterDepartment of Neurosurgery, Manchester Centre for Clinical Neurosciences, Salford Royal NHS Foundation TrustDepartment of Neurosurgery, Manchester Centre for Clinical Neurosciences, Salford Royal NHS Foundation TrustDivision of Neuroscience, School of Biological Sciences, Faculty of Biology, Medicine and Health, The University of ManchesterCentre for Nanotechnology in Medicine, Faculty of Biology, Medicine and Health, The University of ManchesterNanoTherapeutics Lab, Division of Cell Matrix Biology and Regenerative Medicine, School of Biological Sciences, Faculty of Biology, Medicine and Health, University of ManchesterNanoOmics Lab, Division of Cancer Sciences, School of Medical Sciences, Faculty of Biology, Medicine and Health, The University of ManchesterAbstract Glioblastoma (GB) is the most lethal brain cancer, with patient survival rates remaining largely unchanged over the past two decades. Here, we introduce the Nano-omics integrative workflow that links systemic (plasma) and localised (tumour tissue) protein changes associated with GB progression. Mass spectrometry analysis of the nanoparticle biomolecule corona in GL261-bearing mice at different stages of GB revealed plasma protein alterations, even at low tumour burden, with over 30% overlap between GB-specific plasma and tumour tissue proteomes. Analysis of matched plasma and surgically resected tumour samples from high-grade glioma patients demonstrates the clinical applicability of the Nano-omics pipeline. Cross-species correlation identified 48 potential GB biomarker candidates involved in actin cytoskeleton organisation, focal adhesion, platelet activation, leukocyte migration, amino acid biosynthesis, carbon metabolism, and phagosome pathways. The Nano-omics approach holds promise for the discovery of early detection and disease monitoring biomarkers of central nervous system conditions, paving the way for subsequent clinical validation.https://doi.org/10.1038/s41467-025-58252-0 |
| spellingShingle | Xinming Liu Hanan Abmanhal-Masarweh Olivia Iwanowytsch Emmanuel Okwelogu Kiana Arashvand Konstantina Karabatsou Pietro Ivo D’Urso Federico Roncaroli Kostas Kostarelos Thomas Kisby Marilena Hadjidemetriou Plasma-to-tumour tissue integrated proteomics using nano-omics for biomarker discovery in glioblastoma Nature Communications |
| title | Plasma-to-tumour tissue integrated proteomics using nano-omics for biomarker discovery in glioblastoma |
| title_full | Plasma-to-tumour tissue integrated proteomics using nano-omics for biomarker discovery in glioblastoma |
| title_fullStr | Plasma-to-tumour tissue integrated proteomics using nano-omics for biomarker discovery in glioblastoma |
| title_full_unstemmed | Plasma-to-tumour tissue integrated proteomics using nano-omics for biomarker discovery in glioblastoma |
| title_short | Plasma-to-tumour tissue integrated proteomics using nano-omics for biomarker discovery in glioblastoma |
| title_sort | plasma to tumour tissue integrated proteomics using nano omics for biomarker discovery in glioblastoma |
| url | https://doi.org/10.1038/s41467-025-58252-0 |
| work_keys_str_mv | AT xinmingliu plasmatotumourtissueintegratedproteomicsusingnanoomicsforbiomarkerdiscoveryinglioblastoma AT hananabmanhalmasarweh plasmatotumourtissueintegratedproteomicsusingnanoomicsforbiomarkerdiscoveryinglioblastoma AT oliviaiwanowytsch plasmatotumourtissueintegratedproteomicsusingnanoomicsforbiomarkerdiscoveryinglioblastoma AT emmanuelokwelogu plasmatotumourtissueintegratedproteomicsusingnanoomicsforbiomarkerdiscoveryinglioblastoma AT kianaarashvand plasmatotumourtissueintegratedproteomicsusingnanoomicsforbiomarkerdiscoveryinglioblastoma AT konstantinakarabatsou plasmatotumourtissueintegratedproteomicsusingnanoomicsforbiomarkerdiscoveryinglioblastoma AT pietroivodurso plasmatotumourtissueintegratedproteomicsusingnanoomicsforbiomarkerdiscoveryinglioblastoma AT federicoroncaroli plasmatotumourtissueintegratedproteomicsusingnanoomicsforbiomarkerdiscoveryinglioblastoma AT kostaskostarelos plasmatotumourtissueintegratedproteomicsusingnanoomicsforbiomarkerdiscoveryinglioblastoma AT thomaskisby plasmatotumourtissueintegratedproteomicsusingnanoomicsforbiomarkerdiscoveryinglioblastoma AT marilenahadjidemetriou plasmatotumourtissueintegratedproteomicsusingnanoomicsforbiomarkerdiscoveryinglioblastoma |